Author: Denali Therapeutics Inc.

Posted Date:

May 7, 2026

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Denali Therapeutics Inc.

May 7, 2026
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Denali Therapeutics Inc.

April 3, 2026
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

Denali Therapeutics Inc.

March 25, 2026
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Denali Therapeutics Inc.

February 26, 2026
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Denali Therapeutics Inc.

February 8, 2026
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Denali Therapeutics Inc.

February 2, 2026
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Denali Therapeutics Inc.

January 29, 2026